7MM Multiple Sclerosis Diagnosed Cases to Reach 1.64 Million by 2033 Amid Slow Growth

Diagnosed prevalent cases of multiple sclerosis (MS) across the seven major markets (United States, five EU countries, and Japan) are forecasted to rise modestly from 1.61 million in 2024 to 1.64 million by 2033. This represents a slight negative annual growth rate of –0.19%, indicating a stable but slowly expanding disease burden.

GlobalData’s epidemiological analysis highlights that the United States will continue to lead the 7MM in diagnosed MS cases, reaching approximately 896,800 by 2033. In contrast, Japan is projected to maintain the lowest prevalence with around 31,500 diagnosed cases.

What Is Driving This Trend?

• Age Distribution Factors
  Middle-aged adults (50–59) remain the most affected group in the 7MM, reflecting ongoing aging and diagnosis trends.
• Advancements in Detection
  Expanded access to neurologists, MRI technology, and improved clinical awareness have elevated MS detection rates, particularly in early or relapsing–remitting cases.
• Autoimmune and Demographic Influences
  As an autoimmune disorder that mainly affects the central nervous system, MS disproportionately impacts females typically at a 2:1 ratio suggesting hormonal, genetic, and environmental roles.

About Multiple Sclerosis

MS is a chronic autoimmune disease characterized by inflammation, demyelination, and axonal damage within the central nervous system. Presenting most often between ages 20 and 50, MS follows clinical courses such as relapsing–remitting and progressive types. Though incurable, disease-modifying therapies can slow progression, manage symptoms, and reduce relapse rates.

Treatment decisions rely on neurological exams, MRI findings, and laboratory criteria, with early intervention critical to better long-term outcomes. However, there is no definitive cure, and MS remains a leading cause of non-traumatic neuromuscular disability in young to middle-aged adults.

Implications & Outlook

As MS remains a chronic condition with high socioeconomic impact, stable or slightly increasing prevalence underscores the ongoing importance of early diagnosis, therapeutic development, and enhanced patient care. While growth is marginal, the absolute number of affected individuals will continue to demand targeted public health and healthcare planning strategies.